Background
E.I. du Pont de Nemours & Co. (DuPont) and Synvina C.V. were competitors in the chemical industry, specifically in the development of a process for manufacturing 2,5-furan dicarboxylic acid (FDCA) — a chemical building block for polymers, including a sustainable alternative to petroleum-based plastics. Synvina held a patent covering a method of producing FDCA using certain reaction conditions and catalysts.
DuPont had invested significantly in developing its own FDCA manufacturing process, building a pilot plant and conducting research and development that it planned to scale into commercial production. DuPont sought a covenant not to sue from Synvina but was refused. DuPont then filed an IPR petition challenging Synvina’s patent as obvious. The Patent Trial and Appeal Board instituted review but ultimately upheld Synvina’s patent claims as patentable.
DuPont sought to appeal the Board’s decision to the Federal Circuit. Synvina challenged DuPont’s standing to appeal, arguing that because DuPont had not been accused of infringement, it had not suffered a concrete injury giving it the right to seek federal court review.
The Court’s Holding
The Federal Circuit held that DuPont had Article III standing to appeal. The court explained that standing to appeal a PTAB decision requires the same showing required in any civil case: the party must have suffered an injury in fact that is fairly traceable to the challenged action and likely to be redressed by a favorable decision.
Critically, the court held that a company need not wait until it has been sued for infringement — or even accused of infringement — before it has standing to seek review of a patent that threatens its commercial activities. If a party has taken concrete steps toward activities that would create a substantial risk of infringement, and the patent owner has refused to provide a covenant not to sue, that is sufficient to establish an injury in fact. DuPont’s pilot plant, ongoing R&D investments, and concrete plans for commercial FDCA production all placed it in the zone of substantial infringement risk. Combined with Synvina’s refusal to grant a covenant not to sue, DuPont had a controversy of sufficient immediacy and reality to satisfy standing requirements.
The court went on to address the merits and vacated and remanded the Board’s finding that the claims were not shown to be obvious, finding that the Board had applied the wrong burden framework.
Key Takeaways
- An IPR petitioner does not need to be accused of infringement to have Article III standing to appeal an adverse PTAB decision — concrete plans for future commercial activity creating a substantial risk of infringement can suffice.
- A patent owner’s refusal to grant a covenant not to sue, combined with a competitor’s investment in activities within the scope of the patent, creates the necessary controversy for standing.
- Standing for IPR appeals requires the same case-or-controversy analysis applied in Article III courts, meaning that the petitioner’s mere status as a party to the IPR proceeding is not enough — a concrete stake in the outcome is required.
- Companies developing technology or products that may fall within a competitor’s patent should consider filing IPR challenges early, and document their concrete commercial plans to preserve standing to appeal if the IPR does not succeed.
Why It Matters
DuPont v. Synvina is an important decision for companies that use IPR as a competitive tool before a product launch or commercial rollout. Defendants in patent cases typically have standing to appeal because they have been sued. But companies that proactively challenge a competitor’s patent — to clear a path for their own commercial activities — face a different standing question: whether they have enough of a stake in the outcome to invoke federal appellate review.
This decision confirms that pre-launch investments in technology, pilot plants, and R&D programs — even without a pending lawsuit — can establish the concrete injury needed for standing. It provides important guidance to businesses navigating the intersection of IPR strategy and freedom-to-operate analysis: companies that face patent risk from a competitor’s patent should document their commercial plans carefully, and seek a covenant not to sue before challenging the patent at the PTAB, so that a refusal to grant that covenant becomes evidence supporting their standing to appeal an adverse IPR decision.